<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394196</url>
  </required_header>
  <id_info>
    <org_study_id>R01AI120765</org_study_id>
    <secondary_id>R01AI120765</secondary_id>
    <nct_id>NCT03394196</nct_id>
  </id_info>
  <brief_title>RESIST-2: 2nd-line ART for HIV-2 Infection</brief_title>
  <acronym>RESIST-2</acronym>
  <official_title>Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Sante de Ziguinchor, Casamance, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance
      informed 2nd-line ARV implementation study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance
      informed 2nd-line ARV implementation study.

      DURATION

      Up to 3 years

      SAMPLE SIZE

      150

      POPULATION

      HIV-2-infected adults (≥18 years old); ARV-experienced, with virologic failure on 1st-line
      2NRTI+LPV/r in the ISAARV program.

      STRATIFICATION

      By ARV resistance

      REGIMEN OR INTERVENTION

      Intervention: Implement real time ARV resistance testing using rapid DBS/CS ARV Regimens:
      Based on ARV resistance testing

        1. No resistance: Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF
           300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg
           BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) +Enhanced Adherence Counseling

        2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg
           QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC +
           LPV/r + RAL) + Enhanced Adherence Counseling

        3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD
           + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID + Raltegravir 400mg
           BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>up to 3 years</time_frame>
    <description>all cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Loss to follow up</measure>
    <time_frame>1 year</time_frame>
    <description>no contact with study for 1 year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virologic Failure on 2nd line ART</measure>
    <time_frame>up to 3 years</time_frame>
    <description>VL &gt;250 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-2 ARV resistance on 2nd line ART</measure>
    <time_frame>up to 3 years</time_frame>
    <description>by DBS genotyping</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New WHO stage 3 or 4 event &gt; 6 months after starting ART</measure>
    <time_frame>up to 3 years</time_frame>
    <description>BY WHO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 adverse events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>DAIDS definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 T-cell count trajectory</measure>
    <time_frame>up to 3 year after starting 2nd-line ART</time_frame>
    <description>delta CD4 count per year</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HIV-2 Infection</condition>
  <arm_group>
    <arm_group_label>No HIV-2 resistance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-2 NRTI resistance only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-2 NRTI and PI resistance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HIV-2 Genotypic Drug Resistance Testing using DBS</intervention_name>
    <description>Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.</description>
    <arm_group_label>No HIV-2 resistance</arm_group_label>
    <arm_group_label>HIV-2 NRTI resistance only</arm_group_label>
    <arm_group_label>HIV-2 NRTI and PI resistance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)</intervention_name>
    <description>1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling</description>
    <arm_group_label>No HIV-2 resistance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )</intervention_name>
    <description>2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling</description>
    <arm_group_label>HIV-2 NRTI resistance only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)</intervention_name>
    <description>3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling</description>
    <arm_group_label>HIV-2 NRTI and PI resistance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-2 infection: confirmed by Determine (Alere, Inc.) &amp; Immunocomb II (Alere, Inc.) or
             equivalent

          2. Failing 1st line antiretroviral therapy (e.g. AZT/3TC or TDF/XTC + LPV/r; previous 3
             NRTI or 2 NRTI regimens; previous Indinavir (IDV) use, current or previous Atazanavir
             (ATV) use; previous NNRTI use)

          3. For females of reproductive potential: negative serum or urine pregnancy test

          4. Men and women age &gt;/=18 years

          5. Ability and willingness of subject to provide informed consent

        Exclusion Criteria:

          1. HIV-1 or HIV-1/HIV-2 dual infection

          2. Pregnancy or Breast-feeding

          3. Lab Abnormalities

               -  AST/ALT &gt;2.5 X ULN

               -  CrCl &lt;30

          4. Current or previous use of Integrase Inhibitors or Darunavir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey S Gottlieb, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geoffrey S Gottlieb, MD PhD</last_name>
    <phone>206 616-2631</phone>
    <email>gottlieb@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de Sante de Ziguinchor</name>
      <address>
        <city>Ziguinchor</city>
        <state>Casamance</state>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ibrahima Sall, PhD</last_name>
      <phone>221 77 645 3779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Senegal</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Geoffrey S. Gottlieb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD shared on request with ORB approval on final cleaned dataset</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

